184698-41-7

Basic information

• Product Name: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)
• Synonyms: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI);4-Aminotetrahydropyran-4-carboxylic acid methyl ester;Methyl 4-aminotetrahydropyran-4-carboxylate hydrochloride , 95%;Methyl 4-aMinotetrahydro-2H-pyran-4-carboxylate;4-AMinotetrahydro-2H-pyran-4-carboxylic acid Methyl ester;Methyl 4-aMinotetrahydro-2H-pyran-4-carboxylate hydrochloride;Methyl 4-AMinotetrahydropyran-4-carboxylate;methyl 4-aminooxane-4-carboxylate
• CAS NO: 184698-41-7
• Molecular Formula: C₇H₁₃NO₃
• Molecular Weight: 159.184
• Product Categories: CARBOXYLICESTER;pharmacetical
• Mol File: 184698-41-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 223.5°Cat760mmHg
• Flash Point: 87.8°C
• Appearance: /
• Density: 1.128g/cm³
• Vapor Pressure: 0.096mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 6.24±0.20(Predicted)
• CAS DataBase Reference: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(184698-41-7)
• EPA Substance Registry System: 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI)(184698-41-7)

Safety Data

• Hazardous Substances Data: 184698-41-7(Hazardous Substances Data)

Usage

General Description

2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester (9CI) is a chemical compound with the molecular formula C8H13NO3. It is a methyl ester derivative of 4-aminotetrahydropyran-4-carboxylic acid and belongs to the class of pyran carboxylic acids. 2H-Pyran-4-carboxylicacid,4-aminotetrahydro-,methylester(9CI) is used in various chemical and pharmaceutical applications, including as a building block for the synthesis of other organic compounds. It is also used as a research tool in the development of new drugs and chemicals. The chemical properties and potential uses of 2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester (9CI) make it a valuable and versatile chemical in the field of organic chemistry.

InChI:InChI=1/C7H13NO3/c1-10-6(9)7(8)2-4-11-5-3-7/h2-5,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 39124-20-4 4-aminotetrahydro-2H-pyran-4-carboxylic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 50289-12-8 4-amino-tetrahydro-2H-pyran-4-carbonitrile 

Downstream Products

• 720706-20-7 (4-aminotetrahydro-2H-pyran-4-yl)methanol 
• 1326318-32-4 C₁₄H₁₂BrCl₂NO₃ 
• 1326317-70-7 C₂₄H₂₆ClNO₃ 
• 1326317-71-8 C₂₀H₁₆Cl₃NO₃ 
• 1326317-95-6 C₂₈H₃₂ClNO₄ 
• 1326317-99-0 C₂₇H₃₀ClNO₅ 
• 1326318-10-8 C₂₅H₃₀ClNO₄ 
• 1326318-35-7 C₁₅H₁₆BrCl₂NO₄ 

Relevant articles and documents

COMPOUNDS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.

CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

1-Isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50 = 0.89 μM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.